Related Experiment Video
Updated: Sep 7, 2025
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
842
Capecitabine and Hand-foot Syndrome: A Case Report.
Praveen Kumar Uppala1, Anjaly Mary Varghese2, Sree Sudha Tanguturi Yella3
1Santhiram Medical College, Nandyal, Andhra Pradesh, India.
Infectious Disorders Drug Targets
|June 16, 2022
Summary
Capecitabine, a 5-fluorouracil prodrug, can cause hand-foot syndrome (HFS). This report details two cases of localized hyperpigmentation, highlighting the need for greater awareness of this adverse effect.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Capecitabine is an FDA-approved oral prodrug of 5-fluorouracil, widely used for colorectal and breast cancers.
- Mucocutaneous adverse effects are known complications of capecitabine therapy.
- The exact mechanisms underlying these side effects remain unclear, despite proposed theories.
Observation:
- Two cases of capecitabine-induced adverse effects are presented.
- A 59-year-old female developed palmar-plantar hyperpigmentation during capecitabine treatment for sigmoid colon cancer.
- A 42-year-old female experienced similar symptoms after capecitabine administration for stomach adenocarcinoma.
Findings:
- The observed adverse effect was localized cutaneous hyperpigmentation of the palms and soles.
- Symptoms appeared in the second cycle for one patient and the fourth cycle for the other.
- These findings are consistent with hand-foot syndrome (HFS).
Implications:
- Increased awareness of hand-foot syndrome (HFS) associated with capecitabine is crucial for clinicians.
- Early recognition and management of HFS can improve patient compliance and outcomes.
- Further research into the pathogenesis of capecitabine-induced HFS is warranted.
